Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,869,082

« Back to Dashboard
Patent 5,869,082 protects NITROMIST and is included in one NDA. There are three tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has eight patent family members in nine countries.

Summary for Patent: 5,869,082

Title: Buccal, non-polar spray for nitroglycerin
Abstract:A buccal aerosol spray using a non-polar solvent has now been developed which provides nitroglycerin for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal aerosol spray of the invention comprises: propellant 50-95%, non-polar solvent 5-50%, nitroglycerin 0.001-15%, flavoring agent 0.05-5%.
Inventor(s): Dugger, III; Harry A. (Flemington, NJ)
Assignee: Flemington Pharmaceutical Corp. (Flemington, NJ)
Application Number:08/630,064
Patent Claim Types:
see list of patent claims
Composition; Delivery; Formulation; Use; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Mist Pharms Llc
AEROSOL, METERED;SUBLINGUAL021780-001Nov 2, 2006RXYes5,869,082Apr 16, 2016Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,869,082

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria237322<disabled in preview>
Australia1969397<disabled in preview>
Canada2251564<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.